Filing Flows › Immunome (IMNM) › Recalls, complaints & regulation
Immunome (IMNM): clinical trials
Immunome (IMNM) beyond its filings: 6 active clinical trials.
Immunome's latest quarter
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Immunome have?
6 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.